Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composite preparation containing nitrate esters medicine and HMG-CoA reductase inhibitor

A technology of reductase inhibitors and nitrates, which can be used in drug combinations, medical preparations containing active ingredients, active ingredients of heterocyclic compounds, etc. question

Inactive Publication Date: 2006-09-06
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although statins have achieved incomparable effects of other drugs in the primary and secondary prevention of coronary heart disease, but there is still a considerable gap between the ideal curative effect and the development of a more ideal curative effect Anti-myocardial ischemic drugs have a wide market demand and are in line with the interests of patients with cardiovascular diseases
Hyperlipidemia, hypertension, oxidative damage and many factors that induce coronary artery spasm are involved in the occurrence of myocardial ischemic diseases. A single drug has a single mechanism of action and it is difficult to achieve the desired effect. Select two or more Combination of drugs to achieve better results may be an effective way
However, antagonism between drugs may also occur. For example, aspirin and angiotensin-converting enzyme inhibitors alone have a good protective effect on ischemic myocardium, but the clinical efficacy is not clear after combined use. In vitro myocardial culture The experimental results show that there is a significant antagonism between the two

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Combined use of pravastatin and isosorbide mononitrate in the treatment of hyperlipidemia with grade I-II coronary atherosclerosis

[0014] Primary prevention effects in patients with cirrhosis

[0015] 1. Case selection

[0016] The selected patients were hyperlipidemia with grade I-II coronary atherosclerosis, and had not yet developed angina pectoris. They took regular medication at home for primary prevention and did not need to be hospitalized. Those with severe liver and kidney impairment cannot participate in this trial.

[0017] 2. Medication plan

[0018] A total of 252 patients participated in this trial, and all patients were randomly divided into placebo control group, isosorbide mononitrate group, pravastatin group, isosorbide mononitrate+pravastatin group according to blood pressure, blood lipid level and degree of coronary artery stenosis. Vastatin single administration group and isosorbide mononitrate + pravastatin divided administr...

Embodiment 2

[0029] Prevention and treatment effect of lovastatin combined with isosorbide dinitrate in patients with chronic stable angina pectoris

[0030] 1. Case selection

[0031] Patients with chronic stable angina diagnosed according to the World Health Organization's "Nomenclature and Diagnostic Criteria for Ischemic Heart Disease". The selected patients were all chronic stable angina pectoris patients with mild angina pectoris, and they could take medicine routinely at home without hospitalization. Those with severe liver and kidney impairment cannot participate in this trial.

[0032] 2. Medication plan

[0033] A total of 232 patients participated in this test. All patients were randomly divided into isosorbide dinitrate group, lovastatin group, isosorbide dinitrate group, and isosorbide dinitrate group according to age and the number of angina attacks in a week (those with chest tightness longer than 30 minutes were also counted as once). +lovastatin single administration gr...

Embodiment 3

[0045] Prevention and treatment effect of simvastatin combined with isosorbide mononitrate in patients with chronic stable angina pectoris

[0046] 1. Case selection

[0047] Same as clinical trial 2.

[0048] 2. Medication plan

[0049] A total of 253 patients participated in this test. All patients were randomly divided into isosorbide mononitrate group, simvastatin group, isosorbide mononitrate group, Sorbitate + simvastatin single administration group and isosorbide mononitrate + simvastatin multiple administration group. Patients in the isosorbide mononitrate group took 10 mg of isosorbide mononitrate every morning. Patients in the simvastatin group took 15 mg of simvastatin every night before going to bed. Patients in the isosorbide mononitrate + simvastatin single administration group took isosorbide mononitrate 10 mg every morning and simvastatin 15 mg every night before going to bed. Patients in the isosorbide mononitrate + simvastatin multiple administration gro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention supplies a drug composition used to prevent angina of coronary arteryosclerosis patients and cure chronic stable anginapectoris. It contains nitrate medicament and HMG-CoA reductase inhibitor two active components. Its clinical test results indicate: the two active components procure unexpected effect and notable synergism, and this ihas crucial meaning to prevent and betimes cure cardiac muscular ischemic disease, to great degree it improves coronary disease patient prognosis.

Description

technical field [0001] The invention belongs to a new western medicine composition, especially for the prevention of angina pectoris and the treatment of chronic stable angina pectoris in patients with atherosclerosis. Background technique [0002] Nitrate drugs are the most rapid and exact drugs for the treatment of myocardial ischemia. They play an irreplaceable role in the treatment of angina pectoris. Nitroglycerin is a hundred-year-old drug and is still used clinically for angina Treatment, and now such drugs have been greatly developed, and isosorbide mononitrate is an outstanding representative. If the myocardial ischemic disease is not treated in time, the prognosis is very poor, which directly threatens the life of the patient. With the continuous improvement of medical level and the enhancement of patients' awareness of prevention and treatment, early prevention of myocardial ischemic disease has become a common practice for the majority of patients, and it is als...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/34A61K31/366A61K9/20A61K9/48A61P9/10
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com